Tower Research Capital LLC TRC Takes $165,000 Position in F-star Therapeutics, Inc. (NASDAQ:FSTX)

Tower Research Capital LLC TRC purchased a new stake in F-star Therapeutics, Inc. (NASDAQ:FSTX – Get Rating) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 32,298 shares of the company’s stock, valued at approximately $165,000. Tower Research Capital LLC TRC owned 0.15% of F-star Therapeutics as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in FSTX. Envestnet Asset Management Inc. acquired a new stake in F-star Therapeutics during the 1st quarter worth $48,000. JPMorgan Chase & Co. increased its holdings in F-star Therapeutics by 152.7% during the 1st quarter. JPMorgan Chase & Co. now owns 21,335 shares of the company’s stock worth $76,000 after purchasing an additional 12,891 shares in the last quarter. BlackRock Inc. increased its holdings in F-star Therapeutics by 1.6% during the 1st quarter. BlackRock Inc. now owns 295,947 shares of the company’s stock worth $1,050,000 after purchasing an additional 4,776 shares in the last quarter. State Street Corp grew its holdings in shares of F-star Therapeutics by 15.6% in the 1st quarter. State Street Corp now owns 53,150 shares of the company’s stock valued at $189,000 after acquiring an additional 7,180 shares in the last quarter. Finally, Goldman Sachs Group Inc. bought a new position in shares of F-star Therapeutics in the 1st quarter valued at about $120,000. Institutional investors and hedge funds own 31.50% of the company’s stock.

F-star Therapeutics Stock Performance

F-star Therapeutics stock opened at $7.12 on Thursday. F-star Therapeutics, Inc. has a 52 week low of $2.07 and a 52 week high of $7.12. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.38 and a current ratio of 3.38. The stock has a market capitalization of $156.51 million, a P/E ratio of -3.91 and a beta of 0.85. The stock has a 50-day simple moving average of $5.46 and a 200 day simple moving average of $5.65.

F-star Therapeutics Company Profile

(Get Rating)

F-star Therapeutics, Inc is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm’s product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways.